Skip to main content

Table 2 Design characteristics

From: N-acetylcysteine supplementation for the prevention of atrial fibrillation after cardiac surgery: a meta-analysis of eight randomized controlled trials

      

POAF

LOS(days)

Reference

Surgery type

Study design

Control group

Double- blinding

Jadad Score

NAC

Control

NAC

Control

Ozaydin et al. [12]

CABG and/or valve

RCT

(prospective)

Placebo

Yes

4

3/58

12/57

7.7 ± 3

7.9 ± 4.2

Eren et al. [13]

CABG

RCT

(prospective)

Placebo

Yes

3

2/10

1/10

NA

NA

Orhan et al. [14]

CABG

RCT

Routine

protocol

No

3

0/10

1/10

7.2 ± 0.42

7.3 ± 0.48

El-Hamamsy et al. [15]

CABG

RCT

(prospective)

Placebo

Yes

3

4/50

6/50

5.4 ± 2.3

5.3 ± 2.5

Haase et al. [16]#

CABG and/or valve

RCT

Placebo

Yes

5

19/30

16/30

8(7-11)

8(7-11)

Wijeysundera et al. [17]

CABG and/or valve

RCT

Placebo

Yes

5

50/88

58/87

NA

NA

Peker et al. [18]

CABG

RCT

(prospective)

Placebo

Yes

4

0/19

2/21

NA

NA

Kim et al. [19]

CABG

RCT

Placebo

Yes

4

4/24

8/24

11.3 ± 6.3

10.5 ± 4.5

  1. Abbreviations: NAC, N-acetylcysteine; POAF, postoperative atrial fibrillation; LOS, length of hospital stay; CABG, coronary artery bypass grafting; #, history of AF; RCT, randomized controlled trial; NA, data not available